Estrella Immunopharma, Inc. Quarterly Operating Income (Loss) in USD from Q1 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Estrella Immunopharma, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2021 to Q3 2024.
  • Estrella Immunopharma, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$3.38M, a 80.5% decline year-over-year.
  • Estrella Immunopharma, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$8.82M, a 17% decline year-over-year.
  • Estrella Immunopharma, Inc. annual Operating Income (Loss) for 2024 was -$7.31M, a 34.2% increase from 2023.
  • Estrella Immunopharma, Inc. annual Operating Income (Loss) for 2023 was -$11.1M, a 608% decline from 2022.
  • Estrella Immunopharma, Inc. annual Operating Income (Loss) for 2022 was -$1.57M, a 530% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$8.82M -$3.38M -$1.51M -80.5% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$7.31M -$3.95M -$3.78M -2234% Apr 1, 2024 Jun 30, 2024 10-K 2024-09-27
Q1 2024 -$3.53M -$470K +$2.27M +82.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$5.8M -$1.02M +$1.74M +63% Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-14
Q3 2023 -$7.54M -$1.87M +$1.01M +35.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$8.55M -$169K +$255K +60.1% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-01
Q1 2023 -$8.81M -$2.74M -$2.6M -1791% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$6.21M -$2.76M -$3.44M -504% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-14
Q3 2022 -$2.77M -$2.89M -$2.78M -2569% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-20
Q2 2022 $4.71K -$424K -$420K -11807% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-01
Q1 2022 $425K -$145K +$674K +82.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-18
Q4 2021 -$249K $682K Oct 1, 2021 Dec 31, 2021 10-K 2023-03-14
Q3 2021 -$108K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$3.56K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$819K Jan 6, 2021 Mar 31, 2021 10-Q 2022-05-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.